Remove tag better-therapeutics
article thumbnail

A broad range of unmet needs remains in the immuno-oncology space

Pharmaceutical Technology

Immuno-oncology (IO) agents have transformed the cancer therapeutics landscape, driving long-term remissions in a subset of patients who historically had limited options. IO agents include the classes of immune checkpoint modulators, cell therapies, bispecific antibodies, oncolytic viruses, therapeutic vaccines, and cytokines.

article thumbnail

Upcoming sickle cell gene therapies cost effective at $2 million, says ICER

Pharmaceutical Technology

Released on April 12, the report focuses on bluebird bio’s lovotibeglogene autotemcel and Vertex Pharmaceuticals and CRISPR Therapeutics’ exagamglogene autotemcel or exa-cel and their potential use in treating sickle cell disease. Still, comparing the two therapies remains difficult, with ICER rating the evidence as insufficient.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cancer research drugs: Where is the innovation?

Drug Discovery World

The last month has seen huge strides forward in our understanding of cancers, particularly in how they develop resistance to therapies and how we can ‘outsmart’ them using gene editing or different therapeutic pathways, but also how we can better target drugs to individuals and accurately predict treatment outcomes.

Drugs 52
article thumbnail

WHO update on Omicron

The Pharma Data

1.1.529 a variant of concern, named Omicron, on the advice of WHO’s Technical Advisory Group on Virus Evolution (TAG-VE). Researchers in South Africa and around the world are conducting studies to better understand many aspects of Omicron and will continue to share the findings of these studies as they become available.

article thumbnail

Grand Rounds Ethics and Regulatory Series December 9, 2022: The Stepped Wedge Cluster Randomized Trial: Friend or Foe? (Monica Taljaard, PhD; David Magnus, PhD)

Rethinking Clinical Trials

In most cases, a parallel arm or cluster cross would be a better choice. Trialists should work with a biostatistician to come up with the most scientifically robust design given the practical constraints of the study. It’s still important to look at how effective it is and is the juice worth the squeeze in this context?

Trials 130
article thumbnail

Grand Rounds March 24, 2023: From Observational Studies to Pragmatic Clinical Trials: (Almost) A Decade of Research in PCORnet® (Erin Holve, PhD, MPH, MPP; Russell Rothman, MD, MPP; Schuyler Jones, MD; Neha Pagidipati, MD, MPH)

Rethinking Clinical Trials

across all therapeutic areas. It is an independent, nonprofit, research institute and leading funder of patient-centered comparative clinical effectiveness research (CER). Every PCORnet®. Many different types of observational studies are possible with PCORnet®. Those are the areas we are looking at moving forward.

article thumbnail

bluebird bio to split into oncology and gene therapy specialists

pharmaphorum

The companies will be better equipped to deliver on goals and operations will be streamlined and simplified. They will also be better at raising money with tailored investment theses and increased strategic flexibility. million price tag.